MetLife warns shareholders about unsolicited mini-tender offer

MetLife has issued a warning to shareholders against an unsolicited mini-tender offer from Potemkin Limited to acquire shares at $53.00, a 34.42% discount to its market price, advising against participation due to lack of SEC protections. This alert follows MetLife's Q2 2025 results, which saw adjusted earnings of $2.20 per share (down 16% YoY) and revenue of $17.92 billion both miss analyst expectations, prompting BMO Capital and Evercore ISI to lower their price targets for the insurer.

Analysis

MetLife (MET) is facing multiple headwinds, underscored by a strongly negative sentiment score of -0.8. Fundamentally, the company's Q2 2025 performance was weak, with adjusted earnings of $2.20 per share marking a 16% year-over-year decrease. Both earnings per share and quarterly revenue of $17.92 billion missed analyst expectations, with revenue falling 3.4% short of the $18.55 billion forecast. This underperformance prompted downward revisions from analysts; BMO Capital, for instance, lowered its price target to $82 from $90 and cut its forward EPS run-rate for 2025 and 2026 by approximately 4%. While Evercore ISI maintained an Outperform rating, it also trimmed its price target and highlighted disappointing results in the group benefits segment. Compounding this operational weakness is an unsolicited mini-tender offer from Potemkin Limited at $53.00 per share, a steep 34.42% discount to MetLife's recent closing price of $80.82. The company strongly advises shareholders against this offer, noting that such small-scale tenders are structured to avoid key SEC disclosure and procedural requirements, offering investors fewer protections.

Key Decisions for Investors

• Shareholders should follow company guidance and reject the unsolicited mini-tender offer from Potemkin Limited, as its offer price of $53.00 is substantially below the stock's market value.
• Investors should note the recent Q2 earnings and revenue miss, which has triggered price target reductions and a downward revision of forward earnings estimates, signaling potential for continued near-term pressure on the stock.
• Monitor the performance of MetLife's group benefits segment and non-medical health margins in the second half of 2025, as any recovery in these areas could serve as a positive catalyst against the current negative operational trend.